Clinical Data Are Not the Sticking Point: Grace Restructures Manufacturing Path for Intravenous Nimodipine

Patients with aneurysmal subarachnoid hemorrhage are often in intensive care, where coma or difficulty swallowing can make oral medications challenging. Grace Therapeutics hopes to address this gap with GTx-104, an intravenous formulation of nimodipine, but the key to returning it to review by the U.S. Food and Drug Administration (FDA) currently lies not in efficacy trials, but in whether its manufacturing site can pass scrutiny.

Grace released the official minutes obtained following a Type A meeting with the FDA. According to the company, the Complete Response Letter issued by the FDA on April 23 this year did not identify deficiencies in clinical safety or efficacy and did not request new clinical data. Outstanding items include the current good manufacturing practice (cGMP) status of the original contract manufacturing facility, leachables data from additional time points, and a toxicological risk assessment of the excipients. The company must still complete the relevant nonclinical studies.

The manufacturing issue was described as a facility-level compliance matter, rather than a specific quality defect identified in GTx-104 itself, but that distinction does not automatically remove the review obstacle. The original manufacturer must complete remediation and be ready for inspection, after which the FDA may still need to reinspect the facility. As long as the facility remains in an unacceptable compliance status, the application cannot be approved.

To reduce the risk that delays at a single facility will hold up the overall timeline, Grace is transferring the manufacturing process technology to another contract manufacturer located in the United States. A future resubmission could be supported by the original manufacturer, the second supplier, or both. However, the new facility must also generate sufficient stability and analytical data and undergo a product-specific preapproval inspection. The dual-source strategy therefore provides more options, but does not mean that a firm resubmission date has been established.

GTx-104 uses nanoparticle technology to formulate nimodipine, which is poorly soluble in water, as an aqueous formulation that can be infused through a peripheral vein. Its aim is to reduce reliance on nasogastric-tube administration for patients who are comatose or have difficulty swallowing. The company’s previously conducted STRIVE-ON open-label randomized trial enrolled 102 hospitalized patients. Among those receiving GTx-104, 28% experienced at least one episode of clinically significant hypotension judged to be drug-related, compared with 35% in the oral group; overall adverse events were similar between the two groups.

These results indicate that the FDA’s main obstacle at present is not a requirement to repeat clinical development, but the subsequent process also cannot be viewed as a simple matter of submitting supplementary materials. The meeting minutes and Complete Response Letter have not been made public, and the relevant details currently come primarily from company statements. Whether remediation at the original facility, FDA inspections, technology transfer to the new facility, and the nonclinical data can all be completed as planned will collectively determine when—and whether—GTx-104 can once again enter substantive review.